Literature DB >> 18930199

Assessment of ovarian function with anti-Müllerian hormone in systemic lupus erythematosus patients undergoing hematopoietic stem cell transplant.

Hyacinth Browne1, Alicia Armstrong, Alan Decherney, Rebecca Babb, Gabor Illei, James Segars, Steven Pavletic.   

Abstract

In this small pilot study, anti-Müllerian hormone (AMH) levels in women undergoing chemotherapy and hematopoietic stem cell transplantation facilitated earlier identification of impaired ovarian reserve compared with FSH and the resumption of menses. Larger studies are needed to accurately assess the clinical significance of AMH levels in the prediction of long-term reproductive outcomes in reproductive-age transplant patients with our current conditioning regimen.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18930199      PMCID： PMC2843408          DOI： 10.1016/j.fertnstert.2008.08.123

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  13 in total

1.  Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3.

Authors:  Renato Fanchin; Luca Maria Schonäuer; Claudia Righini; Jean Guibourdenche; René Frydman; Joëlle Taieb
Journal:  Hum Reprod       Date:  2003-02       Impact factor: 6.918

2.  Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound.

Authors:  L E Bath; W H B Wallace; M P Shaw; C Fitzpatrick; R A Anderson
Journal:  Hum Reprod       Date:  2003-11       Impact factor: 6.918

3.  Measuring the impact of chemotherapy on fertility in women with breast cancer.

Authors:  Kutluk Oktay; Ozgur Oktem; Andrea Reh; Linda Vahdat
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

4.  Early follicular antimüllerian hormone as an indicator of ovarian reserve.

Authors:  Cem Fiçicioglu; Tayfun Kutlu; Elif Baglam; Zeynep Bakacak
Journal:  Fertil Steril       Date:  2006-03       Impact factor: 7.329

5.  Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.

Authors:  Richard K Burt; Ann Traynor; Laisvyde Statkute; Walter G Barr; Robert Rosa; James Schroeder; Larissa Verda; Nela Krosnjar; Kathleen Quigley; Kimberly Yaung; Marcello Villa Bs; Miyuki Takahashi; Borko Jovanovic; Yu Oyama
Journal:  JAMA       Date:  2006-02-01       Impact factor: 56.272

6.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles.

Authors:  David B Seifer; David T MacLaughlin; Benjamin P Christian; Bo Feng; Robert M Shelden
Journal:  Fertil Steril       Date:  2002-03       Impact factor: 7.329

7.  Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l.

Authors:  E C Larsen; J Müller; C Rechnitzer; K Schmiegelow; A Nyboe Andersen
Journal:  Hum Reprod       Date:  2003-02       Impact factor: 6.918

8.  Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle.

Authors:  S Ueno; T Kuroda; D T Maclaughlin; R C Ragin; T F Manganaro; P K Donahoe
Journal:  Endocrinology       Date:  1989-08       Impact factor: 4.736

9.  Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer.

Authors:  Elisabeth C Larsen; Jørn Müller; Kjeld Schmiegelow; Catherine Rechnitzer; Anders Nyboe Andersen
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

10.  Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition.

Authors:  Ilse A J van Rooij; Isolde den Tonkelaar; Frank J M Broekmans; Caspar W N Looman; Gabrielle J Scheffer; Frank H de Jong; Axel P N Themmen; Egbert R te Velde
Journal:  Menopause       Date:  2004 Nov-Dec       Impact factor: 2.953
View more
  2 in total

1.  Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve.

Authors:  Clara Di Mario; Luca Petricca; Maria Rita Gigante; Angelina Barini; Antonella Barini; Valentina Varriano; Annamaria Paglionico; Paola Cattani; Gianfranco Ferraccioli; Barbara Tolusso; Elisa Gremese
Journal:  Endocrine       Date:  2018-10-15       Impact factor: 3.633

Review 2.  Possible novel biomarkers of organ involvement in systemic lupus erythematosus.

Authors:  Dinglei Su; Rui Liu; Xia Li; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2014-03-06       Impact factor: 2.980
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.